pdcas9 Search Results


93
Addgene inc cmv promoter enhancer
Cmv Promoter Enhancer, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cmv promoter enhancer/product/Addgene inc
Average 93 stars, based on 1 article reviews
cmv promoter enhancer - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

94
Addgene inc inactive bacterial cas9
Bacteria strains and plasmids used in this study
Inactive Bacterial Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inactive bacterial cas9/product/Addgene inc
Average 94 stars, based on 1 article reviews
inactive bacterial cas9 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Addgene inc dcas9 ned
Bacteria strains and plasmids used in this study
Dcas9 Ned, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dcas9 ned/product/Addgene inc
Average 93 stars, based on 1 article reviews
dcas9 ned - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc dcas9 dnmt3a
Bacteria strains and plasmids used in this study
Dcas9 Dnmt3a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dcas9 dnmt3a/product/Addgene inc
Average 93 stars, based on 1 article reviews
dcas9 dnmt3a - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc 2016 addgene plasmid
Bacteria strains and plasmids used in this study
2016 Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2016 addgene plasmid/product/Addgene inc
Average 93 stars, based on 1 article reviews
2016 addgene plasmid - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc pdcas9 j23111
Bacteria strains and plasmids used in this study
Pdcas9 J23111, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdcas9 j23111/product/Addgene inc
Average 93 stars, based on 1 article reviews
pdcas9 j23111 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc plasmid having non targeting nt control guide rnas sgcontrol
Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the <t>sgcontrol</t> MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
Plasmid Having Non Targeting Nt Control Guide Rnas Sgcontrol, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasmid having non targeting nt control guide rnas sgcontrol/product/Addgene inc
Average 93 stars, based on 1 article reviews
plasmid having non targeting nt control guide rnas sgcontrol - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc stanley qi
Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the <t>sgcontrol</t> MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
Stanley Qi, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stanley qi/product/Addgene inc
Average 93 stars, based on 1 article reviews
stanley qi - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc dcas9 tet1 cd
Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the <t>sgcontrol</t> MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
Dcas9 Tet1 Cd, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dcas9 tet1 cd/product/Addgene inc
Average 93 stars, based on 1 article reviews
dcas9 tet1 cd - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Addgene inc pdcas9 plasmid
Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the <t>sgcontrol</t> MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
Pdcas9 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdcas9 plasmid/product/Addgene inc
Average 93 stars, based on 1 article reviews
pdcas9 plasmid - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

94
Addgene inc pdcas9 dnmt3a puror
Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the <t>sgcontrol</t> MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
Pdcas9 Dnmt3a Puror, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdcas9 dnmt3a puror/product/Addgene inc
Average 94 stars, based on 1 article reviews
pdcas9 dnmt3a puror - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

93
Addgene inc harris wang
Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the <t>sgcontrol</t> MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.
Harris Wang, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/harris wang/product/Addgene inc
Average 93 stars, based on 1 article reviews
harris wang - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


Bacteria strains and plasmids used in this study

Journal: Microbial Cell Factories

Article Title: RNA-guided single/double gene repressions in Corynebacterium glutamicum using an efficient CRISPR interference and its application to industrial strain

doi: 10.1186/s12934-017-0843-1

Figure Lengend Snippet: Bacteria strains and plasmids used in this study

Article Snippet: pdCas9-bacteria , p15A(Ec), Cm r , inactive bacterial Cas9 ( Streptococcus pyogenes ), addgene#44249 , [ ] .

Techniques: Bacteria, Plasmid Preparation

Application of the CRISPR interferences in C. glutamicum . a Scheme of the CRISPRi system that requires co-expressing a catalytically inactive version of Cas9 (dCas9) protein and a programmable single guide RNA (sgRNA) for the gene of interest (GOI). dCas9 recognizes the PAM sequence (5′-NGG-3′). A programmable sgRNA with dCas9 was designed to block the binding of RNA polymerase. b Two-plasmid system of the CRISPRi for C. glutamicum : pCoryne-dCas9 expresses dCas9 under the tetA promoter and pCoryne-sgRNA expresses a single sgRNA (base-paring region, dCas9 handle, and S. pyogenes terminator) under a constitutive promoter. c Application of the CRISPRi (dCas9-sgRNA complex) to either the wild-type or l -lysine producer (DM1919) by repressing mRNA expression of the chromosomal pyc gene or gltA gene. d Sequences of the PAM sites (blue) and protospacers (red) for CRISPRi of the pyc or gltA genes. The -35 and -10 regions in the promoter DNA sequence are shown in a box. Transcriptional start sites are shown with black arrows. The start codons for translation are underlined. Specific sgRNA names are shown next to the protospacer. The plasmids containing sgRNAs are listed in Table

Journal: Microbial Cell Factories

Article Title: RNA-guided single/double gene repressions in Corynebacterium glutamicum using an efficient CRISPR interference and its application to industrial strain

doi: 10.1186/s12934-017-0843-1

Figure Lengend Snippet: Application of the CRISPR interferences in C. glutamicum . a Scheme of the CRISPRi system that requires co-expressing a catalytically inactive version of Cas9 (dCas9) protein and a programmable single guide RNA (sgRNA) for the gene of interest (GOI). dCas9 recognizes the PAM sequence (5′-NGG-3′). A programmable sgRNA with dCas9 was designed to block the binding of RNA polymerase. b Two-plasmid system of the CRISPRi for C. glutamicum : pCoryne-dCas9 expresses dCas9 under the tetA promoter and pCoryne-sgRNA expresses a single sgRNA (base-paring region, dCas9 handle, and S. pyogenes terminator) under a constitutive promoter. c Application of the CRISPRi (dCas9-sgRNA complex) to either the wild-type or l -lysine producer (DM1919) by repressing mRNA expression of the chromosomal pyc gene or gltA gene. d Sequences of the PAM sites (blue) and protospacers (red) for CRISPRi of the pyc or gltA genes. The -35 and -10 regions in the promoter DNA sequence are shown in a box. Transcriptional start sites are shown with black arrows. The start codons for translation are underlined. Specific sgRNA names are shown next to the protospacer. The plasmids containing sgRNAs are listed in Table

Article Snippet: pdCas9-bacteria , p15A(Ec), Cm r , inactive bacterial Cas9 ( Streptococcus pyogenes ), addgene#44249 , [ ] .

Techniques: CRISPR, Expressing, Sequencing, Blocking Assay, Binding Assay, Plasmid Preparation

Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the sgcontrol MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

Journal: Cell reports

Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer.

doi: 10.1016/j.celrep.2025.115267

Figure Lengend Snippet: Figure 4. Hypoxia-driven, CTCF-mediated inclusion of exon64A in COL5A1 mRNA pro- motes EMT in breast cancer cells (A) Schematic showing sgRNA sequence target- ing the CTCF motif present immediately down- stream of exon64A. (B and C) CTCF and RNA Pol II ChIP-qPCR on COL5A1 exon64A (B) and RT-qPCR analysis of COL5A1 exon64A and exon64B isoforms normalized to RPS16 and constitutive exon expression levels (C) in MCF7 cells transduced with CRISPR-Cas9-sgRNAs specific against CTCF motif immediately downstream of exon64A in comparison to the sgcontrol MCF7 cells under hypoxia. (D) Immunoblot of GFP (to confirm overexpression of COL5A1 isoforms), E-cad, and vimentin in MCF7 cells with empty vector (EV), COL5A1exon64A, or COL5A1exon64B ectopically expressed in nor- moxic MCF7 cells. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification as a percentage of cells invaded (F) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B in MCF7 cells under hypoxia. (G and H) Representative images (scale bars, 275 mm) (G) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells over- expressing EV, COL5A1exon64A, or COL5A1ex- on64B spheroids under normoxic conditions. (I and J) Invasion assay (scale bars, 200 mm) (I) with its quantification (J) after overexpression of EV, COL5A1exon64A, or COL5A1exon64B iso- forms in CTCF-depleted MCF7 cells in compari- son to the shControl cells under hypoxia. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 biological replicates.

Article Snippet: Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system.

Techniques: Sequencing, ChIP-qPCR, Quantitative RT-PCR, Expressing, Transduction, CRISPR, Comparison, Western Blot, Over Expression, Plasmid Preparation, Invasion Assay, Two Tailed Test

Figure 5. Targeted methylation of CTCF binding site on exon64A by dCas9-DNMT3A blocks CTCF enrichment and leads to reduced inclusion of exon64A in COL5A1 mRNA and EMT under hypoxia (A) Schematic representation of targeting the pu- tative CTCF binding sites immediately down- stream of COL5A1 exon64A by dCas9-DNMT3A with specific sgRNAs to maintain methylation un- der hypoxia to abolish CTCF enrichment. (B) RT-qPCR of COL5A1 exon64A and exon64B in MCF7 cells transfected with dCas9-DNMT3A- sgRNAs or sgcontrol under hypoxia. (C and D) MeDIP-qPCR (C), CTCF-ChIP-qPCR and RNA Pol II ChIP-qPCR (D) in MCF7 cells transfected with either dCas9-DNMT3A-sgcontrol or dCas9-DNMT3A-sg3 under hypoxic condition. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification (F) in MCF7 cells trans- fected with either dCas9-DNMT3A-sgcontrol or dCas9-DNMT3A-sg3 under hypoxic condition. (G and H) Representative images (scale bars, 275 mm) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells transfected with either dCas9-DNMT3A-sgcontrol or dCas9- DNMT3A-sg3 under hypoxic condition. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 bio- logical replicates.

Journal: Cell reports

Article Title: Hypoxia-induced CTCF mediates alternative splicing via coupling chromatin looping and RNA Pol II pause to promote EMT in breast cancer.

doi: 10.1016/j.celrep.2025.115267

Figure Lengend Snippet: Figure 5. Targeted methylation of CTCF binding site on exon64A by dCas9-DNMT3A blocks CTCF enrichment and leads to reduced inclusion of exon64A in COL5A1 mRNA and EMT under hypoxia (A) Schematic representation of targeting the pu- tative CTCF binding sites immediately down- stream of COL5A1 exon64A by dCas9-DNMT3A with specific sgRNAs to maintain methylation un- der hypoxia to abolish CTCF enrichment. (B) RT-qPCR of COL5A1 exon64A and exon64B in MCF7 cells transfected with dCas9-DNMT3A- sgRNAs or sgcontrol under hypoxia. (C and D) MeDIP-qPCR (C), CTCF-ChIP-qPCR and RNA Pol II ChIP-qPCR (D) in MCF7 cells transfected with either dCas9-DNMT3A-sgcontrol or dCas9-DNMT3A-sg3 under hypoxic condition. (E and F) Invasion assay (scale bars, 200 mm) (E) with its quantification (F) in MCF7 cells trans- fected with either dCas9-DNMT3A-sgcontrol or dCas9-DNMT3A-sg3 under hypoxic condition. (G and H) Representative images (scale bars, 275 mm) with their quantification (H) of 3D spheroid invasion assay in MCF7 cells transfected with either dCas9-DNMT3A-sgcontrol or dCas9- DNMT3A-sg3 under hypoxic condition. Error bars, mean ± SEM; two-tailed t test; *p < 0.05, **p < 0.01, and ***p < 0.001; n = 3 bio- logical replicates.

Article Snippet: Additionally, Addgene #71830 plasmid having non-targeting (NT) control guide RNAs (sgcontrol) was used as a control for dCas9-DNMT3A system.

Techniques: Methylation, Binding Assay, Quantitative RT-PCR, Transfection, Methylated DNA Immunoprecipitation, ChIP-qPCR, Invasion Assay, Two Tailed Test